Prima BioMed enters agreement with Fraunhofer Institute for Cell Therapy and Immunology to produce cancer vaccine
The preparation for production of CVac™ for the European trial has already commenced, and Prima BioMed Ltd and the Fraunhofer IZI are working together to prepare the facility to support CVac™ clinical trials in Europe in early 2011. This represents a significant milestone on the pathway to commercialisation of CVac™ in the European market.
Prima Chief Operating Officer and Managing Director for Europe, Matthew Lehman said: “The Fraunhofer Institute is among the foremost research and development organisations in the world and Prima is delighted to enter into this collaborative arrangement (…)”.
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.